Files
Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216952
Peptide-Platinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells
Journal Title
Director/Tutor
Additional contribution
Journal ISSN
Volume Title
Abstract
The relative success of platinum (Pt)-based chemotherapycomes at the cost of severe adverse side effects and is associated with a highrisk of pro-oncogenic activation in the tumor microenvironment. Here, wereport the synthesis of C-POC, a novel Pt(IV) cell-penetrating peptideconjugate showing a reduced impact against nonmalignant cells. In vitro andin vivo evaluation using patient-derived tumor organoids and laser ablationinductively coupled plasma mass spectrometry indicates that C-POCmaintains robust anticancer efficacy while displaying diminished accumulationin healthy organs and reduced adverse toxicity compared to the standard Pt-based therapy. Likewise, C-POC uptake is significantlylowered in the noncancerous cells populating the tumor microenvironment. This results in the downregulation of versican, abiomarker of metastatic spreading and chemoresistance that we found upregulated in patients treated with standard Pt-basedtherapy. Altogether, our findings underscore the importance of considering the off-target impact of anticancer treatment on normalcells to improve drug development and patient care.
Related resource
Subject
Subject (English)
Citation
Citation
LINARES, Jenniffer, et al. Peptide-Platinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells. Journal of Medicinal Chemistry. 2023. Vol. 66, num. 5, pags. 3348-3355. ISSN 0022-2623. [consulted: 12 of October of 2026]. Available at: https://hdl.handle.net/2445/216952